KNB Kanabo Group Plc

TIDMKNB

RNS Number : 3394Z

Kanabo Group PLC

15 May 2023

15 May 2023

Kanabo Group PLC

("Kanabo" or the "Company")

Total Voting Rights

Following the Company's recent Broker Option, which raised GBP200,000 and was completed on 10 May 2023, the Company is pleased to announce that the 6,944,446 ordinary shares issued through the Broker Option have been admitted today, 15 May 2023, to the Standard List of the London Stock Exchange ("Admission")

Following Admission, for the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, Kanabo announces that it has 499,304,946 ordinary shares of 2.5p each in issue ("Ordinary Shares"), each share carrying the right to one vote. The figure of 499,304,946 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please visit http://www.kanabogroup.com/ or contact the following:

Enquiries:

 
Kanabo Group plc                                        via Vigo Consulting 
 Avihu Tamir, Chief Executive Officer                   +44 (0)20 7390 0230 
 Assaf Vardimon, Chief Financial Officer 
 Ian Mattioli, Non-Executive Chair of the 
 Board 
Peterhouse Capital Ltd (Financial Adviser 
 and Broker) 
 Eran Zucker/ Lucy Williams / Charles Goodfellow        +44 (0)20 7469 0930 
Vigo Consulting (Financial Public Relations/Investor 
 Relations) 
 Jeremy Garcia / Fiona Hetherington / Verity 
 Snow                                                        +44 (0)20 7390 
 kanabo@vigoconsulting.com                                             0230 
 

About Kanabo Group Plc

Kanabo Group Plc (LSE:KNB) is a healthtech company committed to revolutionising patient care through its innovative technology platform and disruptive product offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.

Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. The Company is a leader in its field, focusing on improving patient outcomes and providing more accessible healthcare experiences.

In March 2023, Kanabo successfully launched its Pain Clinic, Treat It, under the expert guidance of its technological and product expertise. Treat It initially focuses on chronic pain management using plant-based medicine and treatments that are currently unavailable through traditional channels.

At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.

   Visit   www.kanabogroup.com   for more information. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRBZLLFXELBBBL

(END) Dow Jones Newswires

May 15, 2023 02:00 ET (06:00 GMT)

Kanabo (LSE:KNB)
Historical Stock Chart
From Dec 2024 to Jan 2025

Kanabo (LSE:KNB)
Historical Stock Chart
From Jan 2024 to Jan 2025